Enhanced endothelial delivery and biochemical effects of α-galactosidase by ICAM-1-targeted nanocarriers for Fabry disease.
about
Combination-targeting to multiple endothelial cell adhesion molecules modulates binding, endocytosis, and in vivo biodistribution of drug nanocarriers and their therapeutic cargoes.Distinct subcellular trafficking resulting from monomeric vs multimeric targeting to endothelial ICAM-1: implications for drug deliveryEndothelial cell substrate stiffness influences neutrophil transmigration via myosin light chain kinase-dependent cell contraction.Laronidase-functionalized multiple-wall lipid-core nanocapsules: promising formulation for a more effective treatment of mucopolysaccharidosis type I.A dynamic magnetic shift method to increase nanoparticle concentration in cancer metastases: a feasibility study using simulations on autopsy specimens.Increased glycolipid storage produced by the inheritance of a complex intronic haplotype in the α-galactosidase A (GLA) gene.A fibrinogen-derived peptide provides intercellular adhesion molecule-1-specific targeting and intraendothelial transport of polymer nanocarriers in human cell cultures and miceBiodistribution and endocytosis of ICAM-1-targeting antibodies versus nanocarriers in the gastrointestinal tract in mice.Transport of nanocarriers across gastrointestinal epithelial cells by a new transcellular route induced by targeting ICAM-1.Comparative binding, endocytosis, and biodistribution of antibodies and antibody-coated carriers for targeted delivery of lysosomal enzymes to ICAM-1 versus transferrin receptorChitosan-Alginate Microcapsules Provide Gastric Protection and Intestinal Release of ICAM-1-Targeting Nanocarriers, Enabling GI Targeting In Vivo.Models and methods to evaluate transport of drug delivery systems across cellular barriers.Strategies for delivery of therapeutics into the central nervous system for treatment of lysosomal storage disorders.Enhancing biodistribution of therapeutic enzymes in vivo by modulating surface coating and concentration of ICAM-1-targeted nanocarriers.Intracellular delivery of nanocarriers and targeting to subcellular organelles.Targeted endothelial nanomedicine for common acute pathological conditions.Lysosomal enzyme replacement therapies: Historical development, clinical outcomes, and future perspectives.Targeting, endocytosis, and lysosomal delivery of active enzymes to model human neurons by ICAM-1-targeted nanocarriers.Specific binding, uptake, and transport of ICAM-1-targeted nanocarriers across endothelial and subendothelial cell components of the blood-brain barrier.Clathrin-mediated endocytosis is impaired in type A-B Niemann-Pick disease model cells and can be restored by ICAM-1-mediated enzyme replacement.In vivo performance of polymer nanocarriers dually-targeted to epitopes of the same or different receptors.The role of immune tolerance induction in restoration of the efficacy of ERT in Pompe disease.Effect of flow on endothelial endocytosis of nanocarriers targeted to ICAM-1.Altered Clathrin-Independent Endocytosis in Type A Niemann-Pick Disease Cells and Rescue by ICAM-1-Targeted Enzyme DeliveryEnhanced delivery of α-glucosidase for Pompe disease by ICAM-1-targeted nanocarriers: comparative performance of a strategy for three distinct lysosomal storage disorders.A Comparative Study on the Alterations of Endocytic Pathways in Multiple Lysosomal Storage Disorders.Intercellular adhesion molecule 1 engagement modulates sphingomyelinase and ceramide, supporting uptake of drug carriers by the vascular endothelium.A DNA-Device that Mediates Selective Endosomal Escape and Intracellular Delivery of Drugs and Biologicals.How Carrier Size and Valency Modulate Receptor-Mediated Signaling: Understanding the Link between Binding and Endocytosis of ICAM-1-Targeted Carriers.Co-coating of receptor-targeted drug nanocarriers with anti-phagocytic moieties enhances specific tissue uptake versus non-specific phagocytic clearance.ICAM-1 targeting, intracellular trafficking, and functional activity of polymer nanocarriers coated with a fibrinogen-derived peptide for lysosomal enzyme replacement.α-Galactosidase-A Loaded-Nanoliposomes with Enhanced Enzymatic Activity and Intracellular Penetration.ICAM-1-Targeted Nanocarriers Attenuate Endothelial Release of Soluble ICAM-1, an Inflammatory Regulator.Enhanced Delivery and Effects of Acid Sphingomyelinase by ICAM-1-Targeted Nanocarriers in Type B Niemann-Pick Disease Mice.Targeted delivery of pharmacological chaperones for Gaucher disease to macrophages by a mannosylated cyclodextrin carrier.Monocyte Response to Different Campylobacter jejuni Lysates Involves Endoplasmic Reticulum Stress and the Lysosomal⁻Mitochondrial Axis: When Cell Death Is Better Than Cell Survival.
P2860
Q34119423-33527165-6246-4B49-88E3-EE4FC0BF8A1EQ34631547-C7EF71E5-C3B3-421A-A0EA-3E44C8BBF8EBQ35164276-FB0E3226-E535-4A3A-8B64-5D2F4313C729Q35246598-12808406-5EAC-4326-B9F3-C1E3D7EBF404Q35574714-C8CA9E4B-720B-42DA-95E9-2F04AAFACB0BQ35763202-A26C5CE9-58D8-47F6-A640-CDA67FA53427Q35776839-E4BC2BB5-93EF-4AB4-A359-F38F38FA985EQ36161142-4BD62555-479A-4FAE-A0A5-C12C5A1F1210Q36291228-0552CD6E-8C29-48A4-99D6-53899BCAC026Q36565901-1D48289F-A3FC-4ECD-9785-575222300AEFQ37051502-0DBABEC5-0A15-485E-98BF-DB85B457B504Q37627448-2A15024B-4119-44A1-8873-BEE6C45A2245Q37672410-C60CB1C5-7EB3-4D48-833C-E054BCD941CCQ37724781-B84E8E87-8823-4574-AB21-A601078E5ECBQ38584491-97608742-D40D-428E-9C3F-FF350B42B4EDQ38598987-EED8D767-FFDC-4541-B33F-7E5009BEA127Q38684097-81AEEA69-85B3-42F5-807D-444E7662240CQ38947567-D919C80E-3853-42EA-824F-12EECE893D46Q39021929-F5EBB8E1-5433-495B-8B3A-7B3F101C00C0Q39172670-8DA385E9-6B65-4CE2-B323-85BE702FC6C6Q39273796-CC738227-2D7C-48CC-AA01-D19B50630340Q39663434-0C755882-0260-4B2E-BD5A-BAB629FD0B3AQ40923925-A1302868-B361-4570-B5E6-DF3EADEFBD77Q41035019-AA04214B-13BD-4D8C-BB8C-6C011A12128CQ41121376-3C195902-E3E7-4F13-B81F-D147D457A7DDQ41829569-7BCE8BCF-C39C-4D74-99DB-CF594C52BFB8Q41933986-D722DBE8-824B-4EA2-99A2-B10E9F856104Q42730201-3DC532DD-ED5F-403D-B4BA-A2C1490FA21AQ47276739-74BC771E-B7CD-43CB-9B66-09BFA095EFF1Q47782730-08BC3156-CAEF-4E9D-95F8-0A2F9860B363Q48736822-8B2745F0-5F08-4886-AED8-E13819BAA76EQ50255169-33313ABF-0CC6-42E7-98CA-BB89E95D1BC1Q50887651-FE6A4A75-5065-44D9-BC4B-FBD4EF268693Q50948507-DDEE8C58-FC36-4C52-91BD-46FA2B1C52C0Q51750678-29FCB71E-9E55-4B35-92D0-7405D75EF009Q55481390-8A2D4A52-A392-415C-98AB-2CB1FDBFFDC2
P2860
Enhanced endothelial delivery and biochemical effects of α-galactosidase by ICAM-1-targeted nanocarriers for Fabry disease.
description
2010 nî lūn-bûn
@nan
2010年の論文
@ja
2010年論文
@yue
2010年論文
@zh-hant
2010年論文
@zh-hk
2010年論文
@zh-mo
2010年論文
@zh-tw
2010年论文
@wuu
2010年论文
@zh
2010年论文
@zh-cn
name
Enhanced endothelial delivery ...... anocarriers for Fabry disease.
@en
Enhanced endothelial delivery ...... anocarriers for Fabry disease.
@nl
type
label
Enhanced endothelial delivery ...... anocarriers for Fabry disease.
@en
Enhanced endothelial delivery ...... anocarriers for Fabry disease.
@nl
prefLabel
Enhanced endothelial delivery ...... anocarriers for Fabry disease.
@en
Enhanced endothelial delivery ...... anocarriers for Fabry disease.
@nl
P2093
P2860
P1476
Enhanced endothelial delivery ...... anocarriers for Fabry disease.
@en
P2093
Kishan Kumar
Silvia Muro
Tridib Bhowmick
Yuan Chia Kuo
P2860
P304
P356
10.1016/J.JCONREL.2010.10.031
P407
P577
2010-11-01T00:00:00Z